

- [3] G. Mathé, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J.L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Oxalato-platinum or I-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum, *Biomed. Pharmacother.* 43 (1989) 237–250.
- [4] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, *Cancer Res.* 46 (1986) 6387–6392.
- [5] M. Yatvin, H. Mihlensiepen, W. Porschen, L. Feinendegen, J. Weinstein, Selective delivery of liposome-associated cis-dichloro-diammine platinum (II) by heat and its influence on tumor drug uptake and growth, *Cancer Res.* 41 (1981) 1602–1607.
- [6] R. Perez-Soler, Liposomes as carriers of antitumor agents: toward a clinical reality, *Cancer Treatment Rev.* 16 (1989) 67–82.
- [7] R. Perez-Soler, I. Han, S. Al-Baker, A.R. Khokhar, Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylate leaving groups, *Cancer Chemother.* 33 (1994) 378–384.
- [8] D. Avichezter, B. Schechter, R. Arnon, Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes carboxylates – effect on human ovarian carcinoma, *React. Funct. Polym.* 36 (1998) 59–69.
- [9] B. Schechner, A. Newman, M. Wilnek, R. Arnon, Soluble polymers as carriers of cis-platinum, *J. Control. Release* 39 (1989) 75–87.
- [10] X. Lin, Q. Zhang, J.R. Rice, D.R. Stewart, D.P. Nowotnik, S.B. Howell, Improved targeting of platinum chemotherapeutics. The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models, *Eur J Cancer* 40 (2004) 291–297.
- [11] J.R. Rice, J.L. Gerberich, D. Nowotnik, S.B. Howell, Preclinical efficacy of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system, *Clin. Cancer Res.* 12 (2006) 2248–2254.
- [12] K. Kataoka, G.S. Kwon, M. Yokoyama, Y. Sakurai, T. Okano, Block copolymer micelles as vehicles for drug delivery, *J. Control. Release* 24 (1993) 119–132.
- [13] C. Allen, D. Mysinger, A. Eisenberg, Nano-engineering block copolymer aggregates for drug delivery, *Colloids Surf., B Biointerfaces* 16 (1999) 3–27.
- [14] N. Nishiyama, K. Kataoka, Nano-structured devices based on block copolymer assemblies for drug delivery: designing structures for enhanced drug function, *Adv. Polym. Sci.* 193 (2006) 67–101.
- [15] H.M. Aliabadi, A. Lavasanifar, Polymeric micelles for drug delivery, *Expert Opin. Drug Deliv.* 3 (2006) 139–161.
- [16] N. Nishiyama, M. Yokoyama, T. Aoyagi, T. Okano, Y. Sakurai, K. Kataoka, Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum(II) and poly(ethylene glycol)-poly(a,b-aspartic acid) block copolymer in an aqueous medium, *Langmuir* 15 (1999) 377–383.
- [17] N. Nishiyama, K. Kataoka, Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core, *J Control. Release* 74 (2001) 83–94.
- [18] N. Nishiyama, Y. Kato, Y. Sugiyama, K. Kataoka, Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system, *Pharm. Res.* 18 (2001) 1035–1041.
- [19] N. Nishiyama, F. Koizumi, S. Okazaki, Y. Matsumura, K. Nishio, K. Kataoka, Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles, *Bioconjug. Chem.* 14 (2003) 449–457.
- [20] N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, K. Kataoka, Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice, *Cancer Res.* 63 (2003) 8977–8983.
- [21] H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, T. Kakizoe, Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats, *Br. J. Cancer* 93 (2005) 678–687.
- [22] H. Cabral, N. Nishiyama, S. Okazaki, H. Koyama, K. Kataoka, Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum (II) (DACHPt)-loaded polymeric micelles, *J. Control. Release* 101 (2005) 223–232.
- [23] T. Tashiro, Y. Kawada, Y. Sakurai, Y. Kidani, Antitumor activity of a new platinum complex: oxalato (trans-1,2-diaminocyclohexane) platinum (II): new experimental data, *Biomed. Pharmacother.* 43 (1989) 251–260.
- [24] S. Oppenheimer, Cellular basis of cancer metastasis: a review of fundamentals and new advances, *Acta Histochem.* 108 (2006) 327–334.
- [25] Cervical cancer, NIH Consens. Statement 14 (1996) 1–38.
- [26] A. Lukyanov, Z. Gao, L. Mazzola, V.P. Torchilin, Polyethylene glycol-diacetyl lipid micelles demonstrate increased accumulation in subcutaneous tumors in mice, *Pharm. Res.* 19 (2002) 1424–1429.
- [27] G.S. Kwon, S. Suwa, M. Yokoyama, T. Okano, Y. Sakurai, K. Kataoka, Enhanced tumor accumulation and prolonged circulation times of micelles-forming poly(ethyleneoxide-aspartate) block copolymers-adriamycin conjugates, *J. Control. Release* 29 (1994) 17–23.
- [28] M. Yokoyama, T. Okano, Y. Sakurai, S. Fukushima, K. Okamoto, K. Kataoka, Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system, *J. Drug Target.* 7 (1999) 171–186.
- [29] G. Cavaletti, G. Tredici, M.G. Petruccioli, E. Donde, P. Tredici, P. Marinelli, C. Minoia, A. Ronchi, M. Bayssas, G. Griffon Etienne, Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat, *Eur. J. Cancer* 37 (2001) 2457–2463.
- [30] F. Grolleau, L. Gamelin, M. Boisdon-Celle, B. Lapiet, M. Pelhate, E. Gamelin, A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels, *J. Neurophysiol.* 85 (2001) 2293–2297.
- [31] L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, C. Brezault, M. Le Charpentier, B. Dousset, P. Morel, O. Soubrane, S. Chaussade, G. Mentha, B. Terris, Severe hepatic sinusoidal obstruction associated with oxaliplatin based chemotherapy in patients with metastatic colorectal cancer, *Ann. Oncol.* 15 (2004) 460–466.
- [32] G. Tisman, D. MacDonald, N. Shindell, E. Reece, P. Patel, N. Honda, E.K. Nishimura, J. Garris, W. Shannahan, N. Chisti, J. McCarthy, S.N. Moaddeli, D. Sargent, A. Plant, Oxaliplatin toxicity masquerading as recurrent colon cancer, *J. Clin. Oncol.* 22 (2004) 3202–3204.
- [33] J. Liu, E. Kraut, J. Bender, R. Brooks, S. Balcerzak, M. Grever, H. Stanley, S. D'Ambrosio, R. Gibson-D'Ambrosio, K.K. Chan, Pharmacokinetics of oxaliplatin (NSC266046) alone and in combination with paclitaxel in cancer patients, *Cancer Chemother. Pharmacol.* 49 (2002) 367–374.
- [34] C. Massari, S. Brienza, M. Rotarski, J. Gastiaburu, J.-L. Misset, D. Cupissol, E. Alafaci, H. Dutertre-Catella, G. Bastian, Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function, *Cancer Chemother. Pharmacol.* 45 (2000) 157–164.
- [35] F.R. Luo, S.D. Wyrick, S.G. Chaney, Biotransformations of oxaliplatin in rat blood *in vitro*, *J. Biochem. Molec. Toxicol.* 13 (1999) 159–169.
- [36] F.R. Luo, T.-Y. Yen, S.D. Wyrick, S.G. Chaney, High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin, *J. Chromatogr. B* 724 (1999) 345–356.
- [37] F.R. Luo, S.D. Wyrick, S.G. Chaney, Cytotoxicity, cellular uptake and cellular biotransformations of oxaliplatin in human colon carcinoma cells, *Oncol. Res.* 10 (1998) 595–603.
- [38] E. Jerremalm, P. Videhult, G. Alvelius, W.J. Griffiths, T. Bergman, S. Eksborg, H. Ehrsson, Alkaline hydrolysis of oxaliplatin – isolation and identification of the oxalato monodentate intermediate, *J. Pharm. Sci.* 91 (2002) 2116–2121.

